Pay in 4 interest-free payments of $6.47 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
CJC-1295 DAC Vials (5 mg each): 8 weeks (8 mg total) 2 vials 12 weeks (12 mg total) 3 vials 16 weeks (16 mg total) 4 vials Ipamorelin Vials (5 mg each): 8 weeks (56 days at ~200 mcg/day) 3 vials 12 weeks (84 days) 4 vials 16 weeks (112 days) 5 vials Insulin Syringes (U-100): Per week: 1 (CJC) + 7 (Ipamorelin) = 8 syringes 8 weeks: 64 syringes 12 weeks: 96 syringes 16 weeks: 128 syringes For Ipamorelin doses 10 units, 30- or 50-unit syringes improve accuracy
Interestingly, the GLP-1 receptor agonist, dulaglutide, and the dual GLP-1 and GIP receptor agonist, tirzepatide, are both characterized by a strong delayed gastric emptying upon a single dose administration, but the effect tends to subside as gastric emptying tachyphylaxis is observed after several weeks of treatment
Sermorelin, by contrast, offers a balanced, evidence-informed approach that supports the bodys natural rhythm while minimizing the metabolic risks associated with direct HGH therapy. Sermorelin relies on the intact feedback loop: The brain can still monitor and adjust growth hormone levels whereas HGH may override that, or bypass it, and may be excessive or shut pituitary function down in the process
Primary Risk Factors: Age 50+ (most common demographic for NAION) Sleep apnea (often exceeds Ozempic risk contribution) Hypertension and cardiovascular disease Diabetes mellitus (doubles baseline risk) Small or crowded optic disc anatomy Previous NAION in the opposite eye Sleep apnea deserves special attention
